179 related articles for article (PubMed ID: 17447184)
21. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
24. Inositol in the treatment of trichotillomania and compulsive skin picking.
Seedat S; Stein DJ; Harvey BH
J Clin Psychiatry; 2001 Jan; 62(1):60-1. PubMed ID: 11235935
[No Abstract] [Full Text] [Related]
25. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
26. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
27. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Thomsen PH
J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
[TBL] [Abstract][Full Text] [Related]
28. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
Stein DJ; Montgomery SA; Kasper S; Tanghoj P
Int Clin Psychopharmacol; 2001 Nov; 16(6):357-61. PubMed ID: 11712625
[TBL] [Abstract][Full Text] [Related]
29. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Wolmarans de W; Brand L; Stein DJ; Harvey BH
Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
[TBL] [Abstract][Full Text] [Related]
30. Topiramate augmentation in a patient with obsessive-compulsive disorder.
Van Ameringen M; Patterson B
J Psychiatry Neurosci; 2015 Sep; 40(5):E31-2. PubMed ID: 26290064
[No Abstract] [Full Text] [Related]
31. Commentary: considerations on the pharmacological treatment of compulsions and stereotypies with serotonin reuptake inhibitors in pervasive developmental disorders.
Gordon CT
J Autism Dev Disord; 2000 Oct; 30(5):437-8. PubMed ID: 11098880
[No Abstract] [Full Text] [Related]
32. Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder.
Vulink NC; Westenberg HG; van Nieuwerburgh F; Deforce D; Fluitman SB; Meinardi JS; Denys D
Int J Psychiatry Clin Pract; 2012 Oct; 16(4):277-83. PubMed ID: 22414277
[TBL] [Abstract][Full Text] [Related]
33. Escitalopram prevents relapse of obsessive-compulsive disorder.
Fineberg NA; Tonnoir B; Lemming O; Stein DJ
Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
[TBL] [Abstract][Full Text] [Related]
34. Yawning as a dose-dependent side effect of treatment with escitalopram.
Roncero C; Mezzatesta-Gava M; Grau-López L; Daigre C
Neurologia; 2013; 28(9):589-90. PubMed ID: 22795392
[No Abstract] [Full Text] [Related]
35. Treating obsessive-compulsive disorder.
Long K; Long R
Nurse Pract Forum; 1995 Sep; 6(3):136-7. PubMed ID: 7549614
[No Abstract] [Full Text] [Related]
36. The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.
Bergman J; Pashinian A; Weizman A; Poyurovsky M
Int Clin Psychopharmacol; 2014 Sep; 29(5):263-5. PubMed ID: 24810250
[TBL] [Abstract][Full Text] [Related]
37. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
38. Childhood movement disorders and obsessive compulsive disorder.
Swedo SE; Leonard HL
J Clin Psychiatry; 1994 Mar; 55 Suppl():32-7. PubMed ID: 7915713
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial.
Khan MN; Hotiana UA; Ahmad S
J Ayub Med Coll Abbottabad; 2007; 19(4):58-63. PubMed ID: 18693600
[TBL] [Abstract][Full Text] [Related]
40. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
